Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape
Authors:
Preprint
- 7 May 2024
- preprint
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Abstract
Summary Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense- mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD. This screen revealed disruption of kinase SMG1’s phosphorylation of UPF1 as a potent disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from truncating mutations in vivo and in vitro. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable HLA class I-associated peptides from NMD-downregulated proteins on the surface of cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.Keywords
All Related Versions
This publication has 83 references indexed in Scilit:
- Pharmacologic modulation of RNA splicing enhances anti-tumor immunityCell, 2021
- NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopesiScience, 2021
- Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathwayCancer, 2019
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer CareJAMA Oncology, 2018
- Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivoBiochemical and Biophysical Research Communications, 2017
- Identification of pyrimidine derivatives as hSMG-1 inhibitorsBioorganic & Medicinal Chemistry Letters, 2012
- In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native KinasesChemistry & Biology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A phase i study of emetine hydrochloride (nsc 33669) in solid tumorsCancer, 1973